November 4, 2015 8:33am
The two billion dollar U.S. soft tissue reinforcement market consists of utilizing grafts for the surgical treatment of a broad range of indications. While synthetic grafts have been traditionally used, biologic tissue grafts have offered better results with fewer post-operative complications. It is broadly published that surgical reconstruction procedures benefit from products that provide structural support, and reduce scarring and inflammation. Placental tissues as a cover have such properties; however, the majority of the currently used placental products are dead, dehydrated amniotic membranes lacking sufficient tensile strength and activity.
The Bottom Line: Stravix was developed as a pliable allograft cover with tensile strength that is ten times greater than amniotic membranes alone and designed to offer durability, elasticity, and conformability for surgical procedures. In addition, Stravix retains the properties inherent to the native fresh tissue as a result of Osiris’ proprietary cryopreservation process, BioSmart®.
Osiris (OSIR) closed DOWN -$0.30 to $17.78 after Monday’s advance of $1.05 following Friday’s +$0.60 to $17.03 after being down Thursday -$1.86 to $16.43. Pre-earnings release “jitters” could cause some share pricing “insecurity”, undervalued – On any dip, BUY;
Stravix is a viable cryopreserved human placental tissue comprised of amniotic and connective layers of umbilical tissue that has been developed as a cover specifically for surgical procedures. It retains native components of the tissue including collagen and hyaluronic acid rich extracellular matrix, cytokines, fibroblasts, growth factors, viable endogenous mesenchymal stem cells and epithelial cells. Stravix conforms to the site of injury, requires minimal preparation prior to use and is stored at -75°C to -85°C.
